These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 9256895

  • 1. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer.
    Colleoni M, Graiff C, Vicario G, Nelli P, Sgarbossa G, Pancheri F, Manente P.
    Am J Clin Oncol; 1997 Aug; 20(4):383-6. PubMed ID: 9256895
    [Abstract] [Full Text] [Related]

  • 2. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ, Dunn RL, Hellerstedt B, Cooney KA, Fardig J, Olson K, Pienta KJ, Smith DC.
    Cancer; 2006 Jun 15; 106(12):2617-23. PubMed ID: 16691618
    [Abstract] [Full Text] [Related]

  • 3. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study.
    Smith MR, Kaufman D, Oh W, Guerin K, Seiden M, Makatsoris T, Manola J, Kantoff PW.
    Cancer; 2000 Oct 15; 89(8):1824-8. PubMed ID: 11042579
    [Abstract] [Full Text] [Related]

  • 4. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ, Smith DC.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer.
    Koletsky AJ, Guerra ML, Kronish L.
    Cancer J; 2003 Oct 15; 9(4):286-92. PubMed ID: 12967139
    [Abstract] [Full Text] [Related]

  • 6. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S, Tonato M, Rosi P, De Angelis V, Mearini E, Cesaroni S, Fornetti P, Porena M.
    Cancer; 2000 Mar 15; 88(6):1438-44. PubMed ID: 10717628
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.
    Carles J, Domenech M, Gelabert-Mas A, Nogue M, Tabernero JM, Arcusa A, Guasch I, Miguel A, Ballesteros JJ, Fabregat X.
    Acta Oncol; 1998 Mar 15; 37(2):187-91. PubMed ID: 9636014
    [Abstract] [Full Text] [Related]

  • 8. Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer.
    Attivissimo LA, Fetten JV, Kreis W.
    Am J Clin Oncol; 1996 Dec 15; 19(6):581-3. PubMed ID: 8931676
    [Abstract] [Full Text] [Related]

  • 9. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA, Hoffman PC, Drinkard LC, Watson S, Samuels BL, Golomb HM, Vokes EE.
    Semin Oncol; 1996 Apr 15; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [Abstract] [Full Text] [Related]

  • 10. A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer.
    Carles Galcerán J, Bastus Piulats R, Martín-Broto J, Maroto Rey P, Nogué Aligué M, Domenech Santasusana M, Arcusa Lanza A, Bellmunt Molins J, Colin C, Girard A.
    Clin Transl Oncol; 2005 Mar 15; 7(2):66-73. PubMed ID: 15899211
    [Abstract] [Full Text] [Related]

  • 11. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.
    Pienta KJ, Redman BG, Bandekar R, Strawderman M, Cease K, Esper PS, Naik H, Smith DC.
    Urology; 1997 Sep 15; 50(3):401-6; discussion 406-7. PubMed ID: 9301705
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
    Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ.
    J Clin Oncol; 1999 Jun 15; 17(6):1664-71. PubMed ID: 10561202
    [Abstract] [Full Text] [Related]

  • 13. A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer.
    Sweeney CJ, Monaco FJ, Jung SH, Wasielewski MJ, Picus J, Ansari RH, Dugan WM, Einhorn LH.
    Ann Oncol; 2002 Mar 15; 13(3):435-40. PubMed ID: 11996476
    [Abstract] [Full Text] [Related]

  • 14. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
    Pectasides D, Pectasides E, Papaxoinis G, Koumarianou A, Psyrri A, Xiros N, Tountas N, Kamposioras K, Papatsibas G, Floros T, Gouveris P, Karageorgopoulou S, Economopoulos T.
    Anticancer Res; 2009 Feb 15; 29(2):769-75. PubMed ID: 19331234
    [Abstract] [Full Text] [Related]

  • 15. A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407).
    Pienta KJ, Fisher EI, Eisenberger MA, Mills GM, Goodwin JW, Jones JA, Dakhil SR, Crawford ED, Hussain MH.
    Prostate; 2001 Mar 01; 46(4):257-61. PubMed ID: 11241547
    [Abstract] [Full Text] [Related]

  • 16. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
    Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE.
    J Clin Oncol; 1994 Oct 01; 12(10):2005-12. PubMed ID: 7523606
    [Abstract] [Full Text] [Related]

  • 17. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
    Ferrari AC, Chachoua A, Singh H, Rosenthal M, Taneja S, Bednar M, Mandeli J, Muggia F.
    Cancer; 2001 Jun 01; 91(11):2039-45. PubMed ID: 11391583
    [Abstract] [Full Text] [Related]

  • 18. [Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer].
    Kimura M, Sasagawa T, Tomita Y, Katagiri A, Morishita H, Saito T, Tanikawa T, Kawasaki T, Saito K, Nishiyama T, Kasahara T, Hara N, Takahashi K.
    Hinyokika Kiyo; 2003 Dec 01; 49(12):709-14. PubMed ID: 14978952
    [Abstract] [Full Text] [Related]

  • 19. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
    Mackler NJ, Pienta KJ, Dunn RL, Cooney KA, Redman BG, Olson KB, Fardig JE, Smith DC.
    Clin Genitourin Cancer; 2007 Jun 01; 5(5):318-22. PubMed ID: 17645828
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of vinorelbine in patients with androgen-independent prostate cancer.
    Oudard S, Caty A, Humblet Y, Beauduin M, Suc E, Piccart M, Rolland F, Fumoleau P, Bugat R, Houyau P, Monnier A, Sun X, Montcuquet P, Breza J, Novak J, Gil T, Chopin D.
    Ann Oncol; 2001 Jun 01; 12(6):847-52. PubMed ID: 11484963
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.